← Eichor
Study identifier: NCT06938152 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

Condition: Osteoporosis · Osteoporosis Postmenopausal  ·  Sponsor: National Taiwan University Hospital

PhasePhase 4
Planned participants70
Who can joinFemale, 50 Years to 90 Years
Healthy volunteersNo

About this study

This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.

This description comes directly from the study's public registry record.

Talk to the study team

Fon-Yih Tsuang  ·  886-2312-3456  ·  k880113a@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

National Taiwan University HospitalTaipei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06938152